Our long-term objective is to develop novel cancer therapies employing an attenuated strain of anaerobic bacteria called C. novyi-NT. When injected intravenously, C. novyi-NT spores are not toxic to healthy animals but can selectively germinate and spread within tumors, leading to substantial cures when combined with conventional therapies. Our IND (ref #BB-IND 12698) for C. novyi-NT single-agent therapy has recently been approved by the FDA and we are expecting to initiate a Phase I clinical trial within a month. As this clinical trial and the subsequent Phase II trial will involve C. novyi-NT, a """"""""first-in-class"""""""" anticancer agent, sensitive surrogate makers are urgently needed to meet efficacy and safety concerns. Therefore, in the next funding cycle, our research effort will be focused on the development and validation of biomarkers that can predict therapeutic outcomes. The following specific aims reflect our short-term objectives.
Aim 1. To develop circulating biomarkers for efficacy and toxicity associated with C. novyi-NT therapy in experimental systems: we will investigate three classes of biomarkers in preclinical studies in mice: (1) markers associated with host responses, (2) markers reflecting C. novyi-NT germination and invasion, and (3) markers indicating tumor response.
Aim 2. To assess and develop circulating biomarkers in clinical trials: we will assess the biomarkers and assays developed in the animal models in Phase I and Phase II clinical trials, and validate them in subsequent larger clinical studies.
Aim 3. To develop imaging modalities suitable for monitoring therapeutic responses: we have recently invented a method for imaging bacterial infection with radioactively labeled FIAU in animal models. In this aim, we will develop and implement this method to assess the correlation between C. novyi-NT colonization and treatment responses in both animal models and clinical trials.
Aim 4. To investigate radiolabeled FIAU as a therapeutic agent: we will assess the possibility that [131IJFIAU can generate local radiation sufficiently potent to obliterate the well-oxygenated tumor rims resistant to C. novyi-NT. From the public health perspective, this new therapy we are developing utilizes a special strain of bacteria that only grows within tumors and kills cancer cells resistant to chemo and radiation therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA062924-18
Application #
8319274
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
18
Fiscal Year
2011
Total Cost
$217,834
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Christmas, Brian J; Rafie, Christine I; Hopkins, Alexander C et al. (2018) Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. Cancer Immunol Res 6:1561-1577
Blair, Alex B; Murphy, Adrian (2018) Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. Curr Probl Cancer 42:49-58
Raman, Aadhithya; Lennon, Anne Marie (2018) Cyst Fluid Biomarkers - Diagnosis and Prediction of Malignancy for Cystic Lesions of the Pancreas. Visc Med 34:178-181
Noë, Michaël; Pea, Antonio; Luchini, Claudio et al. (2018) Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1. Mod Pathol 31:1532-1538
Cohen, Joshua D; Li, Lu; Wang, Yuxuan et al. (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359:926-930
Shumar, Stephanie A; Kerr, Evan W; Geldenhuys, Werner J et al. (2018) Nudt19 is a renal CoA diphosphohydrolase with biochemical and regulatory properties that are distinct from the hepatic Nudt7 isoform. J Biol Chem 293:4134-4148
Li, Yuguo; Qiao, Yuan; Chen, Hanwei et al. (2018) Characterization of tumor vascular permeability using natural dextrans and CEST MRI. Magn Reson Med 79:1001-1009
Saung, May Tun; Muth, Stephen; Ding, Ding et al. (2018) Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer 6:118
Canto, Marcia Irene; Almario, Jose Alejandro; Schulick, Richard D et al. (2018) Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology 155:740-751.e2
Makohon-Moore, Alvin P; Matsukuma, Karen; Zhang, Ming et al. (2018) Precancerous neoplastic cells can move through the pancreatic ductal system. Nature 561:201-205

Showing the most recent 10 out of 883 publications